Research to develop point-of-care tests is in progress. Treatment of Buruli ulcer comprises 8 weeks of combined antibiotics (rifampicin and clarithromycin). Complementary therapies such as wound care, skin graft and prevention of disability are needed in some cases to ensure full recovery.
The targ...et set by the World Health Organization (WHO) for control of Buruli ulcer is for countries to achieve a rate of case confirmation by PCR of at least 70%. All endemic countries have at least one PCR facility to support confirmation of cases. However, most countries in the WHO African Region have not been able to reach the target, and the rate of case confirmation has been declining
more
This Tuberculosis guide has been developed jointly by Médecins Sans Frontières and Partners In Health. It aims at providing useful information to the clinicians and health staff for the comprehensive management of tuberculosis. Forms of susceptible and resistant tuberculosis, tuberculosis in child...ren, and HIV co-infection are all fully addressed.
more
The threat posed by Zika virus infection highlights the need to reinforce preparedness arrangements for mosquito-borne diseases in EU/EEA countries, especially for pathogens transmitted by Aedes aegypti and Aedes albopictus.
The aim of this document is to highlight measures that can effectively red...uce the risk of importation and local transmission of pathogens transmitted by Ae. aegypti and Ae. albopictus. The main diseases of concern in this context are Zika, dengue, chikungunya and yellow fever.
more
Rapport sur les populations clés.
Other disorders
Chapter H.5.1
KNCV Tuberculosis Foundation - Your partner in the fight against TB
Accessed November 2017
Epidemic meningitis is a major public health challenge in the African 'meningitis belt', an area that extends from Senegal to Ethiopia with an estimated total population of 500 million. Since 2002, the World Health Organization (WHO), in collaboration with its collaborating centres for meningitis, h...as progressively supported countries in implementing a strategy of ES for meningitis. The strategy is the recommended standard for all countries of the Belt and it is now actively being implemented at different levels in all countries.
more
i. A person who is a contact of a probable or confirmed mpox case in the 21 days before the onset of signs or symptoms, and who presents with any of the following: acute onset of fever (>38.5°C), headache, myalgia (muscle pain/body aches), back pain, profound weakness or fatigue.
OR
ii. A per...son presenting since 01 January 2022 with an unexplained acute skin rash, mucosal lesions or lymphadenopathy (swollen lymph nodes). The skin rash may include single or multiple lesions in the ano-genital region or elsewhere on the body. Mucosal lesions may include single or multiple oral, conjunctival, urethral, penile, vaginal, or ano-rectal lesions. Ano-rectal lesions can also manifest as ano-rectal inflammation (proctitis), pain and/or bleeding.
AND
for which the following common causes of acute rash or skin lesions do not fully explain the clinical picture: varicella zoster, herpes zoster, measles, herpes simplex, bacterial skin infections, disseminated gonococcus infection, primary or secondary syphilis, chancroid, lymphogranuloma venereum, granuloma inguinale, molluscum contagiosum, allergic reaction (e.g., to plants); and any other locally relevant common causes of papular or vesicular rash.
more